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Early relapses in primary CNS lymphoma after response to
polychemotherapy without intraventricular treatment: results of a
phase II study
Abstract
Background A systemic and intraventricular polychemotherapy regimen (the Bonn protocol) without
radiotherapy resulted in durable responses in 75% of patients <60 years with primary CNS lymphoma
(PCNSL), but was complicated by a high rate of Ommaya reservoir infections. Here, the efficacy and
toxicity of this regimen without intraventricular treatment was evaluated in PCNSL. Patients and
methods From August 2003 to November 2005, 18 patients with PCNSL <60 years (median age, 53
years) were treated in a phase II trial with a high-dose methotrexate (MTX; cycles 1, 2, 4 and 5) and
cytarabine (Ara-C; cycles 3 and 6) based systemic therapy including dexamethasone, vinca-alkaloids,
ifosfamide and cyclophosphamide. Results Study accrual was prematurely stopped in November 2005
due to a high rate of early relapses. Seventeen of 18 patients were assessable for response: nine (53%)
achieved complete response (CR), two (12%) complete response/unconfirmed (CRu) and two (12%)
partial response (PR); four (24%) showed progressive disease (PD). One treatment was stopped due to
toxicity. Median follow-up was 23 months, median response duration was only 10 months in responding
patients, and median time to treatment failure (TTF) was 8 months in the whole group. Median overall
survival (OS) has not been reached. Systemic toxicity was mainly hematologic. Conclusions In PCNSL
patients <60 years, polychemotherapy without intraventricular treatment results in a high response rate,
but is associated with early relapses in the majority of cases. This is in contrast to the results achieved
with the same protocol but with intraventricular treatment.
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Background: A systemic and intraventricular polychemotherapy regimen (“Bonn protocol”) 
without radiotherapy had resulted in durable responses in 75% of patients < 60 years with 
primary CNS lymphoma (PCNSL), but had been complicated by a high rate of Ommaya 
reservoir infections. Here, efficacy and toxicity of this regimen without intraventricular 
treatment was evaluated in PCNSL.  
Patients and Methods: From 08/03 to 11/05, 18 patients with PCNSL < 60 years (median age 
53 years) were treated in a phase II trial with a high-dose methotrexate (MTX; cycles 1,2,4 
and 5) and cytarabine (Ara-C; cycles 3,6) based systemic therapy including dexamethasone, 
vinca-alkaloids, ifosfamide and cyclophosphamide.   
Results:  Study accrual was prematurely stopped in 11/05 due to a high rate of early relapses. 
Seventeen/18 patients were assessable for response: Nine (53%) achieved complete response 
(CR), two (12%) complete response/unconfirmed (CRu), two (12%) partial response (PR), 
four (24%) showed progressive disease (PD); one treatment was stopped due to toxicity. 
Median follow-up is 23 months; median response duration was only ten months in responding 
patients and median time to treatment failure (TTF) eight months in the whole group; median 
overall survival (OS) has not been reached. Systemic toxicity was mainly hematologic.   
Conclusions: In PCNSL patients < 60 years polychemotherapy without intraventricular 
treatment results in a high response rate, but is associated with early relapses in the majority 





Primary CNS lymphomas (PCNSL) represent 3.1% of all primary brain tumors in the United 
State[1]; the majority of these are classified as diffuse large cell lymphomas (DLCL) of the B-
cell type[2]. Optimal treatment is not yet defined. In 2003 we have reported the results of a 
pilot/phase II study on a novel combined systemic and intraventricular chemotherapy regimen 
without radiotherapy in 65 consecutive patients.[3] The overall response rate was 71% for the 
whole group, median time to treatment failure (TTF) 21 months, and median overall survival 
(OS) 50 months. Results were significantly better in patients < 60 years of age with a 86% 
overall response rate and a 75% survival fraction at five years. However, Ommaya reservoir 
infection occurred in 19% of the whole group, and represented a serious complication in some 
patients, resulting in interruption or delay of chemotherapy.[3] Therefore, and considering 
data from the literature questioning the benefit of intraventricular chemotherapy in PCNSL[4, 
5], we treated patients with systemic therapy only in a subsequent phase II trial initiated in 
08/2003.      
 
Patients and methods 
Inclusion criteria 
All eligible patients had newly diagnosed histologically proven non-Hodgkin’s lymphoma 
(NHL) according to the REAL- and WHO classification.[6, 7] Patients with lymphoma at 
presentation involving sites other than the brain, meninges, cerebrospinal fluid (CSF) or the 
eyes were not included. Patients to be enrolled in this trial were stratified for age to make sure 
all patients < 60 years of age received the same systemic chemotherapy as previously applied 
in the former pilot/phase II trial[3] but no intraventricular treatment, whereas patients 60 to 75 
years of age received a modified regimen. Therefore, only patients < 60 years of age are 
considered in this analysis.  Exclusion criteria were age <18 years, inadequate bone marrow 
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capacity, defined as neutrophils <1.5 x 109/l, platelets <100 x 109/l, and hemoglobin level 
<8g/dl, known causes of immunosuppression, any previous malignancies, creatinine clearance 
below 60 ml/min, heart insufficiency NYHA grade IIIb, IV, uncontrolled infection or non-
compensated active pulmonary or liver disease. Patients prior treated for PCNSL, except by 
steroids, were not included. Local ethics committees of all participating centers approved the 
study. All patients gave informed consent. 
 
Baseline studies 
Baseline studies were carried out in line with current recommendations of a workshop 
consensus of the International Primary CNS Lymphoma Collaborative Group (IPCG)[8] and 
consisted of magnetic resonance imaging (MRI) of the brain, CSF evaluation, bone marrow 
biopsy and cytology, chest and abdominal computed tomography (CT) and ophthalmologic 
evaluation including slit lamp examination.  
 
Treatment protocol and study design 
The initial protocol has been applied in a pilot/phase II trial including intraventricular therapy 
with MTX, Ara-C and dexamethasone during each cycle[3]. The clinical trial cited here was 
an open-label, non-randomized study. Treatment consisted of six chemotherapy cycles 
separated by two weeks between each cycle. In contrast to the previously published pilot / 
phase II trial [3], neither intraventricular nor intrathecal therapy was administered. Details of 
the protocol are given in Table 1. Systemic chemotherapy was administered as described[3].    
 
 
Evaluation of response and toxicity  
Response was determined after the second and the sixth chemotherapy cycle by contrast 
enhanced MRI of the brain. Response criteria were used as recommended by the IPCG 
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consensus; all respective MRI studies were re-evaluated for this analysis according to these 
criteria[8]: Complete response (CR) was defined as disappearance of all enhancing lesions on 
MRI of the brain in patients being off steroids, unconfirmed complete response (CRu) was 
defined as a minimal residual enhancing lesion in the region of biopsy / hemorrhage without 
change or with involution during follow up, partial response (PR) as a reduction of enhancing 
tumor volume by more than 50%, progressive disease (PD) as increase of tumor volume of 
more than 25% or occurrence of new lesions and stable disease (SD) as any other situation[9]. 
Treatment failure was defined as PD or SD, relapse after initial response, death or 




All patients were followed every three months within the first year after therapy and every six 
months thereafter. Follow-up comprised neurological examination, MRI, CSF examination 
and ophthalmologic evaluation.   
 
Prognostic factors 
The current study population and patients < 60 years of age treated in the former trial with 
systemic and intraventricular chemotherapy[3] were analyzed for factors proposed to have 
prognostic significance[11, 12]. 
 
Neuroradiological findings at relapse 
In order to evaluate if relapse patterns would be different in patients being treated with or 
without intraventricular chemotherapy all MR images at relapse were evaluated and were re-
assessed in the cohort of the former trial. Meningeal involvement was defined as confluent 
leptomeningeal contrast enhancement and was not diagnosed if only juxtameningeal or 
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periventricular lesions were detectable.  
 
Statistics   
Primary endpoint was response. The design of the study was a non-inferiority design: It was 
hypothesized, that the response rate to the treatment protocol would not be inferior to the 
response rate in the published phase II trial (including intraventricular treatment). Assuming 
this response rate of 86%[3], inclusion of 110 patients would result in a response rate of > 
75% with a 95% confidence interval and a power of 90% at a level of significance of 0.05. 
Secondary endpoints were TTF, OS, response duration and treatment related morbidity.  OS 
and TTF were calculated from the date of histological diagnosis to death, treatment failure or 
last date of follow up, respectively. Response duration was defined as the date CR, CRu or PR 
was first documented until date of relapse, disease progression, death of any cause or last 
follow-up, respectively. Relapse or progression was defined as (re)growth of tumor at any site 
within or outside the CNS. TTF and response duration were estimated by the Kaplan-Meier 
method.[13] Annual interim analyses were carried out in order to assess pre-defined criteria 
resulting in premature termination of the trial: 1. A mortality rate due to treatment of > 20% or 
2. A response rate of  < 75%, if the power analysis would then reveal, that the aim of the trial 




Between August 2003 and an interim analysis in November 2005, 44 consecutive patients 
from seven centers were enrolled in this phase II trial. Of these, 18 were < 60 years of age. In 
this age group no component of the prior protocol had been changed with exception of 
omitting intraventricular therapy. Since systemic treatment was modified in patients ≥ 60 
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years, only the results in the younger patients are presented here: Their median age was 53 
years (range, 27 to 59 years), and their median Karnofsky performance score (KPS) was 80% 
(range, 50 to 100%).  
In total, 97 cycles of chemotherapy were administered. Complete treatment without 
modification was given to 10 patients. Four patients received a modification of treatment, 
since a reduction of MTX dosage was necessary due to a transient decrease of creatinine 
clearance. Reasons for incomplete treatment were termination of therapy due to toxicity (one 
patient) and discontinuation of treatment due to PD under therapy (four patients).  
  
Treatment response 
One patient was not assessable for response; because therapy was terminated after the first 
cycle due to hepatotoxicity, grade IV. From the remaining 17, nine (53%) showed CR, two 
(12%) CRu, two (12%) PR. In four (24%) the tumor was progressive despite therapy. None of 
the patients with PR or CRu received any further initial therapy.   
 
Time to treatment failure, overall survival, and response duration 
Follow-up is two to 41 months (median: 23 months) in the whole group and two to 41 months 
(median 24 months) for surviving patients. During follow-up, 14 events defined as treatment 
failures, and four deaths occurred. The Kaplan-Meier estimate for median TTF was eight 
months (95% C.I., 6 to 9 months); the median OS is not yet reached.  The median response 
duration in 13 patients with CR, CRu or PR was ten months (95% C.I., four to 15 months). 
The Kaplan-Meier analysis of response duration is depicted in figure 1a, of TTF in figure 1b 
in comparison to data of patients < 60 years having received the same protocol with inclusion 
of intraventricular treatment[3]. The median response duration in patients of this former trial 
had not been reached after a follow up of three months to 87 months (median 32 months); 
therefore, the difference between response duration/TTF of patients treated with and without 
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intraventricular chemotherapy, is highly significant with p < 0,005/p=0,007. In this former 
trial, median TTF and median OS for patients < 60 years have not yet been reached [3]. 
In order to analyze, if differences in prognostic scores [11,12] may have influenced the 
different outcomes in the current versus the historical study population, these factors were 
evaluated. Data to classify patients according to a prognostic score as published by the 
IELSG[11], were completed for ten out of 18 patients of the current trial and for 24 out of 30 
patients of the former trial. Comparing the different risk scores (IELSG score 0-1: low risk; 2-
3: intermediate risk; 4-5: high risk) there was a trend towards a lower risk of the patients in 
the current trial. All patients from both study groups could also be classified according to the 
Memorial Sloan Kettering Cancer Centre prognostic model[12]. Again, a trend towards a 
better prognostic score for the patients in the current treatment trial could be found when 
applying this model. Both classifications showed no significant difference between the two 
patient groups (data not shown).  
 
Toxicity 
Toxicity could be analyzed in 60 chemotherapy cycles administered in 10 patients. WHO 
grade IV leucopenia (thrombocytopenia) occurred in one patient (two), and was short lasting. 
WHO grade III leucopenia (thrombocytopenia) occurred in three (two) patients. Nine patients 
experienced WHO grade 3/4 infections. Two patients developed episodes of transient 
nephrotoxicity WHO grade II, four suffered from mucositis. In one patient, therapy had to be 
discontinued due to treatment-induced hepatotoxicity, grade IV.  No therapy associated 
cognitive dysfunction was found in any of the patients after chemotherapy or at follow-up; 
however, formal neuropsychometric testing was not carried out. 
 
Treatment at relapse  
In four patients, the disease was progressive; nine patients relapsed. Salvage treatment was 
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carried out according to the treating physician’s decision with different regimens including 
high-dose chemotherapy with stem-cell rescue in three patients (n=1 for PD and n=2 for 
relapse)[14]. All three showed CR. Eight patients were irradiated either at progression (n=3) 
or at relapse (n=5). Three of those showed CR, two achieved a PR, one patient showed a 
stable disease and in two patients a tumor progression was diagnosed. Two patients suffered 
from a second relapse after salvage therapy: One patient, treated with high-dose 
chemotherapy, achieved a CR; the other patient was irradiated and achieved a PR thereafter. 
 
Neuroradiological findings at relapse 
MRI findings at progression or relapse were evaluable in 12 patients. Leptomeningeal 
involvement was found in six/12 patients (one isolated leptomeningeal relapse, five combined 
parenchymatous and leptomeningeal). In six other patients an isolated parenchymatous 
relapse was seen. For localization of primary tumor manifestation and at tumor relapse or 
progression, see table 2. Re-evaluation of MRI scans in patients suffering either from relapse 
(n=6) or PD (n=2) in the former trial with intraventricular therapy[3], showed leptomeningeal 
involvement only in one.  
 
Discussion 
Clinical trials in PCNSL have exploited therapy with high-dose MTX alone[15-17], MTX-
based polychemotherapy[3, 18] and combination of MTX-based chemotherapy with whole 
brain radiotherapy[19-23]. MTX as a sole treatment in two multicenter trials at a dosage of 
8g/m
2 
every 14 days for six cycles has resulted in complete response (CR) rates of 29%/52% 
and in a median survival of 25/55.8, months respectively[16, 24, 25]. Combination chemo-
/radiotherapy has resulted in overall survival rates of up to 60 months[21], however, careful 
follow up has identified a large fraction of such patients suffering from late treatment related 
neurotoxicity[21, 26-28]. Treatment induced neurotoxicity is less frequent in long term 
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survivors after chemotherapy alone for PCNSL[29-31]. Therefore, optimizing chemotherapy 
regimens in order to defer whole brain radiotherapy is essential.  
This trial aimed at reproducing the results after combined systemic and intraventricular 
chemotherapy in PCNSL patients < 60 years of age with a five-year survival fraction of 
75%[3]. Reasons to omit intraventricular therapy in the current trial were a high Ommaya 
reservoir infection rate and data from retrospective analysis putting into doubt the necessity of 
intraventricular treatment[4, 5]. However, an interim analysis two years after initiation of this 
trial revealed an unexpectedly high relapse rate with a median response duration of only ten 
months in responding patients. In comparison, the response duration has not been reached 
after 32 months of median follow- up in the former trial[3]. Though poor response duration 
had not been a predefined criterion for premature study termination, the trial committee 
decided to close the trial after 26 months of patient accrual. At this time 18 patients < 60 years 
had been enrolled and were further followed, 17 of these were evaluable for response.  
The overall response rate in this group was 76% and therefore comparable with the respective 
value of 86% in the former trial[3]. However, time to treatment failure and response duration 
in the whole group as well as response duration in responding patients were significantly 
lower with a significance level of p  < 0.01. In order to analyze whether this difference was 
due to an imbalance of patients with worse clinical prognosis – independent of treatment – we 
evaluated patients of both trials for established prognostic factors[11, 12]. No such differences 
could be detected. Re-evaluation of MR images at relapse in the former and in the current trial 
suggested a higher incidence of leptomeningeal tumor manifestation in patients not treated 
with intraventricular therapy. However, this finding is not sturdy data, since routine CSF 
examination has not been carried out in all patients at relapse.  It is important to point out that 
the majority of patients suffering from either relapse or tumor progression in the current study 
showed response to salvage therapy. In both trials, in the current study and in the former trial, 
overall survival has not been reached yet. However follow up in the current study is rather 
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short therefor is no comparison of overall survival data between the two trials possible.  
Two retrospective analyses addressing the efficacy of intrathecal chemotherapy in PCNSL[4, 
5] did not find the inclusion of this modality influencing survival. Precise dosage, application 
route and schedule of intrathecal therapy were not given in a retrospective analysis on 109 out 
of 363 PCNSL patients treated with heterogeneous regimens including chemotherapy alone, 
radiotherapy (RT) alone, RT followed by chemotherapy and vice versa[4]. However, only 11 
out of the 109 patients treated with intrathecal chemotherapy had not been treated with RT in 
this series[4]. Given the fact that RT is an efficient modality to control lymphomatous 
meningial tumor manifestation, a possible prophylactic or therapeutic effect of intrathecal 
chemotherapy might have been obscured by whole brain RT. In a retrospective single-center 
case-controlled study [5] the outcome of 14 PCNSL patients not being treated with intrathecal 
chemotherapy was compared with that of 28 matched patients having received five serial 
weekly dosages of 12mg MTX via an Ommaya reservoir alternating with systemic MTX. 
Patient groups were balanced for clinical prognostic factors as well as for the percentage 
having received irradiation. Neither event-free survival nor overall survival was influenced by 
the addition of intraventricular therapy in this retrospective case-controlled series.[5] 
Therapeutic differences in this analysis[5] in comparison with our former series[3] were 
dosage, timing and composition of intraventricular treatment. Irrespective of the question, if 
these differences are sufficient to explain the discrepancy between our observation and data in 
the literature, the results of the present trial suggest, that long term tumor control in PCNSL 
with a polychemotherapy regimen developed by our group[3] is only possible, if local 
treatment of the CSF compartment is included. Since in young patients with PCNSL cure is 
the aim, it is disappointing, that just omitting intraventricular treatment leaves this protocol no 
more efficient than other less demanding regimens [15-17]. However, a possible role of the 
CSF compartment as a sanctuary for lymphomatous tumor cells in PCNSL is suggested by 
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this observation, which might be more important in chemotherapy alone protocols than 
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Table 1: Modified Bonn Chemotherapy Protocol for Primary CNS Lymphoma  
 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Cycle A        
Methotrexate i.v. 
(5g/m2)* +       
Vincristine i.v.  
(2 mg) +       
Ifosfamide i.v.  
(800 mg/m2)**  + + + +   
Dexamethasone p.o. 
(10 mg/m2)***  + + + +   
        
Cycle B        
Methotrexate i.v. 
(5g/m2)* +       
Vincristine i.v.(2 mg) +       
Cyclophosphamide 
i.v. (200 mg/m2)**  + + + +   
Dexamethasone p.o. 
(10 mg/m2)***  + + + +   
        
Cycle C        
Ara-C i.v.  
(3 g/m2)+ + +      
Vindesine i.v. (5 mg) +       
Dexamethasone p.o. 




Table 2:  Site of tumor localization at primary diagnosis and tumor relapse / progression 
 
Localization of lesion 
Patient no.  
Parenchymal 
Leptomengial 
as detected by  
 CSF       MRI 
Ocular Systemic 








































































































































Table 1:  
Sequence of cycles: A1 (d. 1-5), B1 (d. 22-26), C1 (d. 43-49); A2 (d. 64-68), B2 (d. 85-89), 
C2 (d. 106-112). Cycles A to C (A1 to C1) are repeated once (A2 to C2) 
 
* 0.5 g/m2 infusion over 30 min and 4.5 g/m2 infusion over 23.5 h 
** 1 h infusion 
*** dexamethasone was given in cycles A2 and B2 only 
+  3 h infusion 
i. v. intravenously 
p. o. orally   
 
Table 2:  
+   tumor  detectable 
- no  tumor detectable 




Figure 1A: Response duration for responding patients according to treatment protocol 
 
Figure 1B:  Time to treatment failure according to treatment protocol 
 
 
 
 
 
 
  
